Home > News

News

Glaxo Wellcome UK Limited (T/A Allen & Hanburys), Glaxo Group Limited v Sandoz Limited, Sandoz International GMBH [2017] EWCA Civ 2276 April 2017Martin Howe QC and Iona Berkeley represented the Respondents, “Sandoz”, in Glaxo’s Appeal against the decision of HHJ Hacon refusing permission to join two additional defendants to its claim for passing off. Glaxo alleged passing off on the basis that Sandoz had marketed asthma inhalers similar to Glaxo’s ‘Seratide’ inhalers in the UK. Glaxo had […]
Varian Medical Systems International AG vs (1) Elekta Ltd, (2) Elekta Holdings Ltd [2017] EWHC 712 (Pat).6 April 2017James Abrahams QC and James Whyte successfully represented the Defendants (“Elekta”) in Varian’s claim for infringement of its patent for a combined MRI and radiotherapy device. Elekta denied that its combined MRI and radiotherapy machine infringed the Patent, and further claimed that the Patent was invalid for insufficiency, obviousness and added matter. The judge held […]
Unwired Planet International Ltd v (1) Huawei Technologies Co. Ltd (2) Huawei Technologies (UK) Co. Ltd5 April 2017Adrian Speck QC, Isabel Jamal and Tom Jones appeared for the Claimant, Unwired Planet, and Andrew Lykiardopoulos QC appeared for the Defendant, Huawei, in a landmark action concerning the nature of a patent holder’s obligations to license Standard Essential Patents (SEPs) on Fair, Reasonable and Non-Discriminatory (FRAND) terms. In a much-anticipated judgment, Birss J found […]
Congratulations to our Door Tenant Eleonora Rosati on her promotion4 April 20178 New Square congratulate Eleonora Rosati on her promotion to Associate Professor in Intellectual Property Law at the University of Southampton.
Teva UK Ltd v Merck Sharp & Dohme Corp [2017] EWHC 539 (Pat)21 March 2017Charlotte May QC and Lindsay Lane represented the first claimant (“Teva”) in its successful challenge of the defendant’s (“Merck”) supplementary protection certificate (SPC) for an anti-viral drug marketed as Atripla. The SPC covered a combination of the active ingredient efavirenz together with emtricitabine and tenofovir. The Court agreed with Teva’s case that the SPC failed […]